ライフサイエンスコーパス: acute respiratory distress syndrome

1 7% veno-venous) for medical indications (78% acute respiratory distress syndrome).

2 Consecutive subjects with acute respiratory distress syndrome.

3 y associated with a lower incidence of early acute respiratory distress syndrome.

4 tients by increasing their susceptibility to acute respiratory distress syndrome.

5 ractive option for future clinical trials in acute respiratory distress syndrome.

6 ies on pulmonary vascular mechanics in early acute respiratory distress syndrome.

7 educe the severity of rodent E. coli-induced acute respiratory distress syndrome.

8 and at 3, 6, 12, 24, 36, and 48 months after acute respiratory distress syndrome.

9 lung-protective ventilation in patients with acute respiratory distress syndrome.

10 associated with lower mortality in pediatric acute respiratory distress syndrome.

11 ne it in predicting outcome in patients with acute respiratory distress syndrome.

12 ive end-expiratory pressures in experimental acute respiratory distress syndrome.

13 European Consensus Conference definition of acute respiratory distress syndrome.

14 e ventilation 11.4% of the time patients had acute respiratory distress syndrome.

15 lung-protective ventilation in patients with acute respiratory distress syndrome.

16 l volume ventilation lowers mortality in the acute respiratory distress syndrome.

17 iving greater than or equal to 2 years after acute respiratory distress syndrome.

18 le ventilation may depend on the etiology of acute respiratory distress syndrome.

19 associated with lung stress and mortality in acute respiratory distress syndrome.

20 us indirect lung injury leading to pediatric acute respiratory distress syndrome.

21 the main pathophysiologic mechanisms of the acute respiratory distress syndrome.

22 erably with low tidal volume ventilation for acute respiratory distress syndrome.

23 ssociated with lung connective tissue during acute respiratory distress syndrome.

24 through the emergency department at risk for acute respiratory distress syndrome.

25 placebo for patients with sepsis-associated acute respiratory distress syndrome.

26 eolar permeability, and organ dysfunction in acute respiratory distress syndrome.

27 in system-modulating agents for treatment of acute respiratory distress syndrome.

28 s a major risk factor for the development of acute respiratory distress syndrome.

29 ed for developing age-tailored therapies for acute respiratory distress syndrome.

30 ased in broncho-alveolar lavage fluid during acute respiratory distress syndrome.

31 ed trial of conservative fluid management in acute respiratory distress syndrome.

32 in experimental pulmonary and extrapulmonary acute respiratory distress syndrome.

33 k of chronic inflammatory diseases including acute respiratory distress syndrome.

34 iratory distress syndrome and extrapulmonary acute respiratory distress syndrome.

35 ease (AERD), inflammatory bowel disease, and acute respiratory distress syndrome.

36 associated with the inflammatory cascade of acute respiratory distress syndrome.

37 pulmonary infiltrates, meeting criteria for acute respiratory distress syndrome.

38 ociated with poor prognosis in patients with acute respiratory distress syndrome.

39 g of mechanical ventilation in patients with acute respiratory distress syndrome.

40 or mechanical ventilation and development of acute respiratory distress syndrome.

41 steroids and beta agonists for prevention of acute respiratory distress syndrome.

42 bserved during mechanical ventilation in the acute respiratory distress syndrome.

43 after T cell therapy; five met criteria for acute respiratory distress syndrome.

44 17 years old, with moderate/severe pediatric acute respiratory distress syndrome.

45 s enrolled in previously completed trials of acute respiratory distress syndrome.

46 e are associated with mortality in pediatric acute respiratory distress syndrome.

47 studied 778 patients with moderate to severe acute respiratory distress syndrome.

48 PaO2:FIO2 ratio, gender, and the etiology of acute respiratory distress syndrome.

49 We measured circulating interleukin-17A in acute respiratory distress syndrome 1 and acute respirat

50 In both acute respiratory distress syndrome 1 and acute respirat

51 In acute respiratory distress syndrome 1, we used paired se

52 ring drainage (1.7% vs 9.9%, P = 0.006), and acute respiratory distress syndrome (1.7% vs 9.9%, P = 0

53 Of 457 patients with acute respiratory distress syndrome, 106 (23%) were not

54 th acute respiratory distress syndrome 1 and acute respiratory distress syndrome 2, elevated interleu

55 piratory distress syndrome onset, whereas in acute respiratory distress syndrome 2, we used plasma ob

56 in acute respiratory distress syndrome 1 and acute respiratory distress syndrome 2.

57 More patients in the placebo group developed acute respiratory distress syndrome (7 vs 0) and require

58 Acute respiratory distress syndrome adjudication was per

59 h (odds ratio, 2.43; 95% CI, 1.68-3.49), and acute respiratory distress syndrome after accounting for

60 ients had a 73% increased risk of developing acute respiratory distress syndrome after controlling fo

61 ate into fibrocytes; 2) the influence of the acute respiratory distress syndrome alveolar environment

62 eriod, 469 patients (18 tuberculosis-related acute respiratory distress syndrome and 451 acute respir

63 cts were categorized as tuberculosis-related acute respiratory distress syndrome and acute respirator

64 open avenues for therapeutic manipulation in acute respiratory distress syndrome and could have impli

65 ion improved lung function in both pulmonary acute respiratory distress syndrome and extrapulmonary a

66 y of phosphoinositide 3-kinase inhibition in acute respiratory distress syndrome and highlight the im

67 n is detectable in over 90% of patients with acute respiratory distress syndrome and is associated wi

68 on can result in serious outcomes, including acute respiratory distress syndrome and multi-organ fail

69 nchoalveolar lavage fluid from patients with acute respiratory distress syndrome and multiple models

70 f clinical trials of promising therapies for acute respiratory distress syndrome and reduce the numbe

71 Twenty-five patients (19 mild-to-severe acute respiratory distress syndrome and six matched vent

72 randomized clinical trial of hypothermia in acute respiratory distress syndrome and the feasibility

73 used commonly for diagnosis of lung injury (acute respiratory distress syndrome and transfusion-rela

74 ns, trauma, infection, sepsis, endotoxin and acute respiratory distress syndrome) and matched mouse m

75 enrolled, including 47 meeting criteria for acute respiratory distress syndrome, and 32 failed nonin

76 y ill patients with sepsis and septic shock, acute respiratory distress syndrome, and major trauma ha

77 tay, lower incidence of acute kidney injury, acute respiratory distress syndrome, and need for vasopr

78 ary vascular resistance predict mortality in acute respiratory distress syndrome, and pulmonary arter

79 ptic shock, multiple organ failure including acute respiratory distress syndrome (ARDS) and acute ren

80 in the intensive care unit (ICU) at risk of acute respiratory distress syndrome (ARDS) and how venti

81 Although acute respiratory distress syndrome (ARDS) and progressi

82 Sepsis and the acute respiratory distress syndrome (ARDS) are major cau

83 urported to help drive early pathogenesis in acute respiratory distress syndrome (ARDS) by enhancing

84 HapMap3 was also associated with the risk of acute respiratory distress syndrome (ARDS) in an intensi

85 Acute respiratory distress syndrome (ARDS) is associated

86 RATIONALE: Acute respiratory distress syndrome (ARDS) is caused by

87 Acute respiratory distress syndrome (ARDS) is characteri

88 Acute respiratory distress syndrome (ARDS) is undefined

89 ventilation (MV) remains the cornerstone of acute respiratory distress syndrome (ARDS) management.

90 re (PEEP) is unknown in patients with severe acute respiratory distress syndrome (ARDS) on extracorpo

91 l patient data meta-analysis was to identify acute respiratory distress syndrome (ARDS) patient subgr

92 ration on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remain uncert

93 RATIONALE: Acute respiratory distress syndrome (ARDS) remains a maj

94 Management of acute respiratory distress syndrome (ARDS) remains large

95 Clinical factors alone poorly explain acute respiratory distress syndrome (ARDS) risk and ARDS

96 RATIONALE: We previously identified two acute respiratory distress syndrome (ARDS) subphenotypes

97 Clinicians who treat patients with acute respiratory distress syndrome (ARDS) use informati

98 In the 50 years since acute respiratory distress syndrome (ARDS) was first des

99 RATIONALE: Following acute respiratory distress syndrome (ARDS), joblessness

100 a novel virus that emerged in 2012, causing acute respiratory distress syndrome (ARDS), severe pneum

101 In clinical trials of therapies for acute respiratory distress syndrome (ARDS), the average

102 nderstanding and management of patients with acute respiratory distress syndrome (ARDS), the morbidit

103 ecause severe pneumonia is the main cause of acute respiratory distress syndrome (ARDS), we aimed to

104 za A viruses (IAV) can cause lung injury and acute respiratory distress syndrome (ARDS), which is cha

105 l ventilation since the first description of acute respiratory distress syndrome (ARDS).

106 echanical ventilation in adult patients with acute respiratory distress syndrome (ARDS).

107 ocused on consensus definition of sepsis and acute respiratory distress syndrome (ARDS).

108 ing endotracheal intubation in patients with acute respiratory distress syndrome (ARDS).

109 anagement, and outcomes of patients with the acute respiratory distress syndrome (ARDS).

110 (NIV) is increasingly used in patients with acute respiratory distress syndrome (ARDS).

111 utic effects have never been investigated in acute respiratory distress syndrome (ARDS).

112 e growth factor (KGF) might be beneficial in acute respiratory distress syndrome (ARDS).

113 ical in the management of many patients with acute respiratory distress syndrome (ARDS).

114 syndrome has been as extensively studied as acute respiratory distress syndrome (ARDS).

115 s emerged as a potential new therapeutic for acute respiratory distress syndrome (ARDS).

116 s, management, and outcomes of patients with acute respiratory distress syndrome (ARDS).

117 50th anniversary of the first description of acute respiratory distress syndrome (ARDS).

118 Acute kidney injury and acute respiratory distress syndrome are both independent

119 y targeting lung injury in patients with the acute respiratory distress syndrome are lacking.

120 hospitalized patients at risk of developing acute respiratory distress syndrome at the time of criti

121 Patients with acute respiratory distress syndrome at the time of initi

122 Retrospective review of 58 patients with acute respiratory distress syndrome based on Berlin crit

123 Mechanically ventilated children with acute respiratory distress syndrome (Berlin).

124 nous extracorporeal membrane oxygenation for acute respiratory distress syndrome between 2010 and 201

125 Acute respiratory distress syndrome blood and alveolar n

126 depletion decreased the inhibitory effect of acute respiratory distress syndrome broncho-alveolar lav

127 P replenishment of serum amyloid P-depleted acute respiratory distress syndrome broncho-alveolar lav

128 Acute respiratory distress syndrome broncho-alveolar lav

129 on may serve as rescue therapy in refractory acute respiratory distress syndrome but has not been ass

130 stress syndrome compared with extrapulmonary acute respiratory distress syndrome but preserved E-cadh

131 ies suggest hypothermia may be beneficial in acute respiratory distress syndrome, but cooling causes

132 In pulmonary acute respiratory distress syndrome, but not in extrapul

133 After induction of acute respiratory distress syndrome by hydrochloric acid

134 and beta agonists may reduce progression to acute respiratory distress syndrome by reducing lung inf

135 Only 7 of 133 acute respiratory distress syndrome cases met criteria f

136 ia is a major cause of acute lung injury and acute respiratory distress syndrome, characterized by al

137 The diseases reviewed include acute respiratory distress syndrome, chronic obstructive

138 present a promising therapeutic strategy for acute respiratory distress syndrome, clinical translatio

139 in biologic marker expressions in pulmonary acute respiratory distress syndrome compared with extrap

140 In acute respiratory distress syndrome, conservative fluid

141 Acute respiratory distress syndrome continues to represe

142 e oxygenation index over the first 7 days of acute respiratory distress syndrome could discriminate b

143 he presence of fibrocytes in the lung during acute respiratory distress syndrome could result in a ba

144 Acute respiratory distress syndrome criteria were record

145 t intubated at the time of meeting all other acute respiratory distress syndrome criteria.

146 anti-inflammatory cytokines were measured on acute respiratory distress syndrome day 1 and correlated

147 udy of mechanically ventilated patients with acute respiratory distress syndrome demonstrates that im

148 In total, 133 cases of acute respiratory distress syndrome developed in 2,635 p

149 Acute respiratory distress syndrome developed in 75 pati

150 Median time to acute respiratory distress syndrome development was 55.4

151 Patients were screened for acute respiratory distress syndrome development within 1

152 s in sepsis that correlate with survival and acute respiratory distress syndrome development, thus su

153 onal clinical indices were not predictive of acute respiratory distress syndrome development.

154 atio, and plateau pressure at 24 hours after acute respiratory distress syndrome diagnosis was associ

155 driving pressure evaluated at 24 hours after acute respiratory distress syndrome diagnosis while vent

156 ss syndrome due to tuberculosis behaves like acute respiratory distress syndrome due to other causes

157 Acute respiratory distress syndrome due to tuberculosis

158 In pulmonary acute respiratory distress syndrome, E-cadherin expressi

159 During the acute respiratory distress syndrome, epithelial cells, p

160 d with volume-controlled ventilation in both acute respiratory distress syndrome etiologies.

161 on compared with nonventilated regardless of acute respiratory distress syndrome etiology.

162 Tuberculosis is an uncommon cause of acute respiratory distress syndrome even in high tubercu

163 mbrane oxygenation therapy in case of severe acute respiratory distress syndrome failing conventional

164 Most cases of acute respiratory distress syndrome following hematopoie

165 intravenous infusion early in the course of acute respiratory distress syndrome for patients with a

166 clinical criteria for sepsis (six trials) or acute respiratory distress syndrome (four trials), use o

167 children with indirect lung injury pediatric acute respiratory distress syndrome have a lower risk of

168 at both incidence and mortality of pediatric acute respiratory distress syndrome have not changed ove

169 tio, 3.73; 95% CI, 2.39-5.82; p < 0.001) and acute respiratory distress syndrome (hazard ratio, 2.16;

170 s old), reason for connection different from acute respiratory distress syndrome, higher simplified a

171 and variable ventilation; in extrapulmonary acute respiratory distress syndrome, however, it was hig

172 with adverse prognosis in patients with the acute respiratory distress syndrome; however, the progno

173 s, respiratory insufficiency in 141 (11.6%), acute respiratory distress syndrome in 84 (6.9%), pulmon

174 t that the susceptibility to and severity of acute respiratory distress syndrome in children could di

175 Our understanding of the acute respiratory distress syndrome in children is limit

176 orticosteroid receipt and the development of acute respiratory distress syndrome in critically ill pa

177 leads to defective T and B cell function and acute respiratory distress syndrome in early childhood.

178 in experimental animals and diseases such as acute respiratory distress syndrome in humans.

179 Acute kidney injury increases the risk of acute respiratory distress syndrome in mechanically vent

180 een associated with adverse prognosis in the acute respiratory distress syndrome in small and single-

181 ds were associated with a lower incidence of acute respiratory distress syndrome in the 96 hours afte

182 iction Score identifies patients at risk for acute respiratory distress syndrome in the emergency dep

183 e of extracorporeal membrane oxygenation for acute respiratory distress syndrome in this group.

184 etter understand the risk factors underlying acute respiratory distress syndrome in this population,

185 The incidence and outcomes of acute respiratory distress syndrome in this setting are

186 Forty-two patients with acute respiratory distress syndrome in whom airflow, air

187 ain significant gaps in our understanding of acute respiratory distress syndrome, in part due to the

188 Acute respiratory distress syndrome is a frequent compli

189 The acute respiratory distress syndrome is a frequent condit

190 Acute respiratory distress syndrome is a multifactorial

191 Whether tuberculosis-related acute respiratory distress syndrome is associated with w

192 RATIONALE: Acute respiratory distress syndrome is characterized by

193 udesonide/formoterol in patients at risk for acute respiratory distress syndrome is feasible and impr

194 c impact of pulmonary arterial compliance in acute respiratory distress syndrome is not established.

195 Acute respiratory distress syndrome is refractory to pha

196 Acute respiratory distress syndrome led to pulmonary vas

197 Serum amyloid P was located in normal and acute respiratory distress syndrome lung by immunohistoc

198 In pediatric acute respiratory distress syndrome, lung injury is medi

199 In a reciprocal multivariate analysis, acute respiratory distress syndrome (n = 299; 36%) demon

200 ride administered intratracheally (pulmonary acute respiratory distress syndrome, n = 12) or intraper

201 n = 12) or intraperitoneally (extrapulmonary acute respiratory distress syndrome, n = 12).

202 In this experimental model, Acute Respiratory Distress Syndrome Network and open lun

203 pulmonary vascular mechanics was similar in Acute Respiratory Distress Syndrome Network and open lun

204 Forty-one Acute Respiratory Distress Syndrome Network hospitals ac

205 Forty-two ICUs across 17 Acute Respiratory Distress Syndrome Network hospitals.

206 ized to 4 hours ventilation according to the Acute Respiratory Distress Syndrome Network protocol or

207 ty and ventilator-free day outcomes in three Acute Respiratory Distress Syndrome Network studies used

208 Open lung approach as compared to Acute Respiratory Distress Syndrome Network was associat

209 omarker levels in 194 patients, including 38 acute respiratory distress syndrome nonsurvivors.

210 ds were associated with a lower incidence of acute respiratory distress syndrome (odds ratio for 30 m

211 significantly associated with development of acute respiratory distress syndrome (odds ratio, 1.31; 9

212 to 4 was associated with the development of acute respiratory distress syndrome (odds ratio, 4.17; 9

213 2, p=0.041), the most frequent of which were acute respiratory distress syndrome (one [2%] vs two [4%

214 In extrapulmonary acute respiratory distress syndrome, only volume-control

215 olume, Cdyn, and PaO2/FIO2 were collected at acute respiratory distress syndrome onset and at 24 hour

216 low tidal volume ventilation within 1 day of acute respiratory distress syndrome onset for greater th

217 tidal volume during the first 72 hours after acute respiratory distress syndrome onset was never less

218 At acute respiratory distress syndrome onset, neither mecha

219 ge fluid samples obtained within 48 hours of acute respiratory distress syndrome onset, whereas in ac

220 low tidal volume ventilation within 1 day of acute respiratory distress syndrome onset.

221 sion of tumorigenicity-2) within 24 hours of acute respiratory distress syndrome onset.

222 were treated with high-flow nasal cannula at acute respiratory distress syndrome onset.

223 asal cannula and those who were intubated at acute respiratory distress syndrome onset.

224 ndardized ventilator settings 24 hours after acute respiratory distress syndrome onset.

225 CI, 1.21-1.42) and the composite outcome of acute respiratory distress syndrome or death (odds ratio

226 17; 95% CI, 2.26-7.72), composite outcome of acute respiratory distress syndrome or death (odds ratio

227 ated acute respiratory distress syndrome and acute respiratory distress syndrome-others and were mana

228 acute respiratory distress syndrome and 451 acute respiratory distress syndrome-others) with acute r

229 lated acute respiratory distress syndrome vs acute respiratory distress syndrome-others; 27.7% vs 28.

230 rome, we lack a scoring system that predicts acute respiratory distress syndrome outcome with high pr

231 sitivity troponin I (Abbott ARCHITECT), with acute respiratory distress syndrome outcomes, we measure

232 ctive analysis of all subjects admitted with acute respiratory distress syndrome over the last 16 yea

233 ay in patients with early moderate to severe acute respiratory distress syndrome (PaO2/FiO2 < 200 and

234 rome (PaO2/FIO2 </= 300) and moderate-severe acute respiratory distress syndrome (PaO2/FIO2 </= 150).

235 on methods better identified moderate-severe acute respiratory distress syndrome (PaO2/FIO2 </= 150);

236 the curve for patients meeting criteria for acute respiratory distress syndrome (PaO2/FIO2 </= 300)

237 acute respiratory distress syndrome than non-acute respiratory distress syndrome patients (48% vs 18%

238 the bedside to predict the risk of death of acute respiratory distress syndrome patients 24 hours af

239 ved our model using individual data from 478 acute respiratory distress syndrome patients and assesse

240 ic withdrawal than moderate/severe pediatric acute respiratory distress syndrome patients managed wit

241 ess syndrome and the feasibility of studying acute respiratory distress syndrome patients receiving n

242 in-33) were higher in both groups of matched acute respiratory distress syndrome patients than in bot

243 alone does not cause hypothermia but allowed acute respiratory distress syndrome patients to be effec

244 following: 1) the ability of monocytes from acute respiratory distress syndrome patients to differen

245 of biomarkers of inflammation and injury to acute respiratory distress syndrome patients undergoing

246 One thousand fifty-seven acute respiratory distress syndrome patients were includ

247 ies treated with high-flow nasal cannula and acute respiratory distress syndrome patients who were di

248 Nine hundred thirty-four ventilated acute respiratory distress syndrome patients with a cent

249 ive fluid management decreases mortality for acute respiratory distress syndrome patients with a low

250 Prospective hypothermia treatment in eight acute respiratory distress syndrome patients with PaO2/F

251 Obesity has a complex impact on acute respiratory distress syndrome patients, being asso

252 ts replicability in a separate cohort of 300 acute respiratory distress syndrome patients.

253 sal cannula patients should be considered as acute respiratory distress syndrome patients.

254 ssays for various pulmonary diseases such as acute respiratory distress syndrome, pneumonia, cystic f

255 s (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrome, pneumonia, decubitu

256 In pediatric acute respiratory distress syndrome, pro- and anti-infla

257 inical trial of hypothermia in patients with acute respiratory distress syndrome receiving treatment

258 We assessed the incidence and mortality of acute respiratory distress syndrome reported in children

259 iated with worse outcomes when compared with acute respiratory distress syndrome secondary to other c

260 chanically ventilated burn patients, whereas acute respiratory distress syndrome similarly demonstrat

261 gan Failure Assessment, PaO2/FIO2, origin of acute respiratory distress syndrome, steroids, renal fai

262 A derivation cohort from three acute respiratory distress syndrome studies was used to

263 Then, for each individual acute respiratory distress syndrome study, the threshold

264 , pulmonary arterial compliance increased in acute respiratory distress syndrome survivors and remain

265 ospital discharge, greater than one third of acute respiratory distress syndrome survivors had muscle

266 Given high co-occurrence, acute respiratory distress syndrome survivors should be

267 ychiatric symptoms occurred in two thirds of acute respiratory distress syndrome survivors with frequ

268 In a multisite cohort of long-term acute respiratory distress syndrome survivors, better an

269 right ventricular load improve over time in acute respiratory distress syndrome survivors.

270 tudies evaluating the 4-m gait speed test in acute respiratory distress syndrome survivors.

271 One hundred fifty-six acute respiratory distress syndrome survivors.

272 fter multivariable adjustment, age, cause of acute respiratory distress syndrome, temperature, heart

273 lity was 22% and was significantly higher in acute respiratory distress syndrome than non-acute respi

274 dherin in lung tissue only in extrapulmonary acute respiratory distress syndrome, thus suggesting low

275 ume ventilation, the mean (SD) percentage of acute respiratory distress syndrome time it was used was

276 s the impact of right ventricular protective acute respiratory distress syndrome treatment on right v

277 Acute respiratory distress syndrome trials powered for m

278 omprehensive studies of myocardial injury in acute respiratory distress syndrome using modern high-se

279 distress syndrome, but not in extrapulmonary acute respiratory distress syndrome, variable ventilatio

280 l blood mononuclear cells were isolated from acute respiratory distress syndrome, ventilated controls

281 between the two groups (tuberculosis-related acute respiratory distress syndrome vs acute respiratory

282 -based and PICU-based incidence of pediatric acute respiratory distress syndrome was 3.5 (95% CI, 2.2

283 Acute respiratory distress syndrome was induced by Esche

284 Acute respiratory distress syndrome was induced by repea

285 Acute respiratory distress syndrome was induced combinin

286 Mild acute respiratory distress syndrome was induced in 10 an

287 Acute respiratory distress syndrome was induced in rats

288 The main reason for acute respiratory distress syndrome was pneumonia in 81%

289 In lung tissue from patients with acute respiratory distress syndrome, we identified incre

290 eement on the characteristic features of the acute respiratory distress syndrome, we lack a scoring s

291 e respiratory distress syndrome-others) with acute respiratory distress syndrome were admitted.

292 ial proportion of critically ill adults with acute respiratory distress syndrome were not intubated i

293 patients (5%) with moderate/severe pediatric acute respiratory distress syndrome were supported on ex

294 and six matched ventilated controls without acute respiratory distress syndrome) were enrolled.

295 ways were associated with the development of acute respiratory distress syndrome, whereas other tradi

296 d emergency department patients experiencing acute respiratory distress syndrome while in the emergen

297 retrospective analysis of 363 subjects with acute respiratory distress syndrome who had complete bas

298 lminant pneumonia that rapidly progresses to acute respiratory distress syndrome with a fatal outcome

299 The unadjusted occurrence rate of acute respiratory distress syndrome within 96 hours of I

300 After inducing acute respiratory distress syndrome, Z0 and effective ar